Dr. Michael Chen

Biotech Science Reporter

Molecular biologist turned biotech journalist with PhD in Genetics and 9 years of experience covering drug discovery, clinical trials, and regulatory approvals. Former research scientist who transitioned to journalism to explain breakthrough therapies and biotechnology innovations. Specializes in gene therapy, immunotherapy, rare disease treatments, and the science behind novel drug mechanisms.

AI Author, more information here

Insmed’s June 2026 Update: SEC Compliance, Insider Sales, and a 3,000‑Patient Brensocatib Trial in Europe

Insmed’s June 2026 update reveals insider‑trade compliance and a major European trial of brensocatib for bronchiectasis, aiming to transform treatment and guide future approvals.

Dr. Michael Chen

26/06/2026, 21:10

3 minutes to read

Danaher Shares Surge: Operational Excellence Fuels Life‑Science Growth & Investor Confidence

Danaher Corp’s share rally shows investors confidence in its operational excellence and cutting‑edge life‑science innovations—an attractive entry point for science‑driven growth.

Dr. Michael Chen

26/06/2026, 09:51

4 minutes to read

Merck KGaA Shares Rise, Voting Structure Stable as Pharma Rides Innovation Momentum

Merck KGaA’s shares stay solid in the DAX, backed by transparent voting rights and a strong pipeline of targeted therapies that promise future growth.

Dr. Michael Chen

25/06/2026, 22:44

3 minutes to read

AbbVie Accelerates Growth: Apogee Acquisition, New Boey® Launch, & Expanded Skyrizi & Maviret Approvals

AbbVie’s acquisition of Apogee Therapeutics and new approvals for Skyrizi, Maviret, and Boey® boost its portfolio across atopic dermatitis, psoriasis, and aesthetic medicine, offering faster, safer treatments and expanding market reach.

Dr. Michael Chen

24/06/2026, 23:38

4 minutes to read

Merck Partners with Saturnus Bio to Target Rare Genetic Cardiomyopathies with Gene‑Modulation Therapies

Merck partners with Saturnus Bio to develop RNA‑ and CRISPR‑based gene‑modulation therapies for rare genetic cardiomyopathies, aiming for faster, more precise treatments.

Dr. Michael Chen

24/06/2026, 20:58

4 minutes to read

Pfizer Faces Trial Setback but Pushes Targeted Therapies & China Growth

Pfizer’s latest oncology trial setback, strategic China push and obesity‑sector gains reveal how the company balances clinical risk with global growth ambitions.

Dr. Michael Chen

24/06/2026, 19:19

2 minutes to read

Pfizer’s Lung‑Cancer ADC Trial Falls Flat, Yet Q1 Earnings Surpass Forecasts

Pfizer’s latest phase‑III ADC trial for lung‑cancer shows no survival benefit, yet the company’s robust portfolio and Q1 2026 earnings remain strong, underscoring resilience amid ongoing oncology trials.

Dr. Michael Chen

23/06/2026, 10:01

4 minutes to read

Incyte Wins Japanese Approval for Minjuvi + Lenalidomide in Refractory DLBCL

Incyte’s Minjuvi plus lenalidomide gains Japanese approval for relapsed or refractory DLBCL, delivering durable 58‑60% response rates with manageable safety and boosting treatment options for patients ineligible for stem‑cell transplant.

Dr. Michael Chen

20/06/2026, 22:59

4 minutes to read

Pfizer CFO Exit: 2026 Guidance Unchanged, Pipeline & Strategy Stay On Course

Pfizer CFO Dave Denton’s June 2026 departure won’t change its FY‑2026 guidance or pipeline plans, keeping revenue targets steady while the drug company pursues oncology and mRNA innovations.

Dr. Michael Chen

20/06/2026, 15:51

4 minutes to read

Revolution Medicines COO Trades Shares: 10(b)(5) Insider Trading & Governance Review

Revolution Medicines COO Margaret Horn’s insider trades reveal how executive equity activity under a 10(b)(5) plan can boost investor confidence and align management with shareholder interests.

Dr. Michael Chen

19/06/2026, 09:55

3 minutes to read

Newer articles Older articles